Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for CV Sciences (CVSI) over the last 14 years, with Q3 2025 value amounting to $4.8 million.

  • CV Sciences' Total Current Liabilities fell 2209.02% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 2209.02%. This contributed to the annual value of $6.1 million for FY2024, which is 9.81% down from last year.
  • Latest data reveals that CV Sciences reported Total Current Liabilities of $4.8 million as of Q3 2025, which was down 2209.02% from $5.7 million recorded in Q2 2025.
  • CV Sciences' Total Current Liabilities' 5-year high stood at $14.9 million during Q1 2021, with a 5-year trough of $4.8 million in Q3 2025.
  • Its 5-year average for Total Current Liabilities is $9.2 million, with a median of $6.1 million in 2024.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 2434.26% in 2021, then crashed by 5685.31% in 2023.
  • Quarter analysis of 5 years shows CV Sciences' Total Current Liabilities stood at $14.5 million in 2021, then fell by 7.93% to $13.3 million in 2022, then plummeted by 54.07% to $6.1 million in 2023, then fell by 0.1% to $6.1 million in 2024, then fell by 21.66% to $4.8 million in 2025.
  • Its Total Current Liabilities stands at $4.8 million for Q3 2025, versus $5.7 million for Q2 2025 and $5.3 million for Q1 2025.